Scrip
AstraZeneca's Iressa gets EU approval for subgroup of NSCLC patients
03 July 2009
Malini Guha
Please Login to read the full article.
03 July 2009
Malini Guha
AstraZeneca's EGFR-targeted anticancer Iressa (gefitinib) has received approval in the EU from the
European Commission for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations in the EGFR (epidermal growth factor receptor).This...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
